What are NXL's recent SEC filings?
Alumni Capital LP, along with Alumni Capital GP LLC and Ashkan Mapar, filed an amended Schedule 13G reporting beneficial ownership of 9.99% of Nexalin Technology's common stock, based on warrants and purchase agreements that are subject to a 9.99% ownership cap. The filing states the fund currently owns no shares but has the right to acquire 40,323 shares upon warrant exercise.
View full filing details →GreenLight Ventures, LLC filed an amended Schedule 13D reporting beneficial ownership of 133,475 shares (approximately 10.8%) of Nexalin Technology, issued as consideration for the sale of PONM, Inc. under a May 2026 Stock Purchase Agreement, including 87,301 third-tranche shares issued November 10, 2026.
View full filing details →Nexalin Technology filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results including revenue, expenses, and balance sheet data. The filing also discloses subsequent ATM program activity through November 12, 2026.
View full filing details →Nexalin Technology filed a definitive proxy statement for a special meeting on December 4, 2026, seeking stockholder approval to issue shares to Alumni Capital LP under an Any Market Purchase Agreement in excess of 20% of outstanding shares, as required by Nasdaq Listing Rule 5635(d).
View full filing details →Nexalin Technology, Inc. had a registration statement declared effective by the SEC, allowing the company to proceed with a securities offering.
View full filing details →Nexalin Technology filed an amendment to its Form S-1 registration statement, including the consent of its independent auditor CBIZ CPAs P.C. for incorporation by reference of its audit report for fiscal year 2025.
View full filing details →Nexalin Technology entered into a 10-year exclusive distribution agreement with INOVANEXA MEDICAL TECHNOLOGIES S.A. (Nexalin LATAM) to distribute its Nexalin Sync neurostimulation device across seven South American countries, with an initial 100-device commercialization program and a requirement to establish local manufacturing in Brazil after 30 devices.
View full filing details →Nexalin Technology received Nasdaq confirmation that it has regained compliance with the $1.00 minimum bid price requirement, but must still demonstrate compliance with the $2,500,000 minimum stockholders' equity requirement by January 4, 2027 to avoid delisting.
View full filing details →Nexalin Technology received a Nasdaq Hearings Panel notice granting continued listing subject to conditions: demonstrating compliance with the minimum bid price requirement by September 28, 2026, and the stockholders' equity requirement by January 4, 2027.
View full filing details →A Schedule 13D was filed regarding Nexalin Technology, Inc., indicating a holder has acquired a greater than 5% beneficial ownership stake with potential activist intent. The filing details are not fully available in the provided text.
View full filing details →Showing 10 of 11 filings. See all filings with SEPT X-Ray
Has NXL ever done a stock split?
What is NXL's share float?
Get Real-Time NXL Intelligence
SEPT X-Ray combines SEC filings with price targets, support/resistance levels, and smart money tracking — updated every 30 minutes.
Try SEPT X-Ray Free